Premium
Experimental local therapy of human melanoma with lytic magainin peptides
Author(s) -
Sloballe Peter W.,
Lee Maloy W.,
Myrga Michelle L.,
Jacob Leonard S.,
Herlyn Meenhard
Publication year - 1995
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910600225
Subject(s) - magainin , peptide , lytic cycle , human skin , antimicrobial peptides , melanoma , cytolysis , cancer research , biology , in vitro , chemistry , immunology , biochemistry , cytotoxicity , virus , genetics
Magainin peptides and model amphipathic peptides exhibit antibiotic activity and are also cytolytic for transformed human cells. Here we demonstrate in vitro that MSI‐511 (an all‐D amino‐acid model magainin peptide) and MSI‐130 (a magainin analogue) were more lytic for 17 human melanomas than for normal melanocytes. Melanomas established s.c. in athymic nude mice and then injected once with the peptide MSI‐511 completely disappeared in 6 out of 9 animals, whereas a control peptide had no effect. Murine skin at the tumor injection site was initially affected, but healed within 2 weeks with minimal scarring. Similarly, accelerated healing was seen in human skin grafted to SCID mice and injected with MSI‐511. Our results indicate that lytic magainin peptides can be used for local tumor therapy with minimal long‐term damage to normal tissues. © 1995 Wiley‐Liss, Inc.